辰欣药业及子公司拟使用闲置自有资金不超29亿元进行委托理财及证券投资

Core Viewpoint - Chenxin Pharmaceutical (603367) announced plans to utilize idle funds for entrusted wealth management and securities investment, with a total amount not exceeding 2.9 billion yuan, aiming to enhance the efficiency of fund usage and generate higher returns for shareholders [1] Group 1: Investment Plans - The company and its subsidiaries plan to use idle self-owned funds for entrusted wealth management and securities investment, with a total limit of 2.9 billion yuan, including up to 2.3 billion yuan for entrusted wealth management and up to 600 million yuan for securities investment [1] - The investment aims to improve the efficiency of idle funds while ensuring that the company's main business operations and daily capital needs are not affected [1] Group 2: Investment Types - Entrusted wealth management will primarily involve bank wealth management products, income certificates, and funds from financial institutions [1] - Securities investment will focus on government bonds or reverse repos, bonds, ETFs, stocks, and other investments permitted by laws and regulations [1]